DDInter1491 DDInter1698
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Pomalidomide {u} (Compound) binds {v} (Gene) CRBN
CRBN {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Pomalidomide (Compound) binds CRBN (Gene) and CRBN (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Pomalidomide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan